Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …

Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is
responsible for the majority of cancer-related deaths worldwide. The management of …

Background Platinum-based chemotherapy is the recommended adjuvant treatment for
patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the …

Background Osimertinib is a third-generation epidermal growth factor receptor–tyrosine
kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI–sensitizing and EGFR T790M …

Antibodies targeting the immune checkpoint molecules PD-1, PD-L1 and CTLA-4,
administered alone or in combination with chemotherapy, are the standard of care in most …

Lung cancer is the most common cause of cancer-related deaths globally. Although smoking-
related lung cancers continue to account for the majority of diagnoses, smoking rates have …

PURPOSE We report CNS efficacy of first-line osimertinib plus chemotherapy versus
osimertinib monotherapy in patients with epidermal growth factor receptor (EGFR)–mutated …

The discovery of a pathogenic variant in the alpha-synuclein (SNCA) gene in the Contursi
kindred in 1997 indisputably confirmed a genetic cause in a subset of Parkinson's disease …

Importance Neoadjuvant therapy combining programmed cell death 1 (PD-1) and
programmed death ligand 1 (PD-L1) inhibitors with platinum-based chemotherapy has …

The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is
transforming due to the approval of novel adjuvant and neoadjuvant systemic treatments …